6-(acetylamino)-N-methylhexanamide | 51504-50-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 6-(acetylamino)-N-methylhexanamide
• 英文别名: 6-acetamido-N-methylhexanamide
• CAS: 51504-50-8
• 化学式: C₉H₁₈N₂O₂
• mdl: MFCD19595825
• 分子量: 186.254
• InChiKey: QBRXAOMAJRIUBJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  13
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.777
• 拓扑面积：
  58.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  6-乙酰氨基己酸甲酯 、 甲胺 以 水 为溶剂， 反应 16.0h， 以90%的产率得到6-(acetylamino)-N-methylhexanamide
  参考文献：
  名称：

  Chemical differentiating agents. Differentiation of HL-60 cells by hexamethylenebis[acetamide]analogs

  摘要：

  Hexamethylenebis[acetamide] (HMBA) is an agent in clinical trial that induces differentiation of certain types of tumor cells to nonmalignant phenotypes. In an attempt to discover a more potent compound, a number of bis-functionalized amides, imides, and hydrazine derivatives of HMBA were prepared and evaluated in vitro with the HL-60 human promyelocytic leukemia cell line. Among the compounds evaluated, the 5,5-dimethylhydantoin derivative is almost 10 times more potent than HMBA in inducing differentiation. The bis-imide, diacetyl-HMBA, is both more potent and effective than its parent compound. Six of the 16 compounds evaluated cause at least 20% differentiation. An inverse relationship between the degree of differentiation and the percentage of viable cells is described for HMBA and its analogues.

  DOI：

  10.1021/jm00385a025

文献信息

• HACES A.; BREITMAN T. R.; DRISCOLL J. S., J. MED. CHEM., 30,(1987) N 2, 405-409
  作者：HACES A.、 BREITMAN T. R.、 DRISCOLL J. S.

  DOI：——

  日期：——
• US4882346A
  申请人：——

  公开号：US4882346A

  公开（公告）日：1989-11-21
• US4992472A
  申请人：——

  公开号：US4992472A

  公开（公告）日：1991-02-12
• US7335768B2
  申请人：——

  公开号：US7335768B2

  公开（公告）日：2008-02-26
• Chemical differentiating agents. Differentiation of HL-60 cells by hexamethylenebis[acetamide]analogs
  作者：Alberto Haces、Theodore R. Breitman、John S. Driscoll

  DOI：10.1021/jm00385a025

  日期：1987.2

  Hexamethylenebis[acetamide] (HMBA) is an agent in clinical trial that induces differentiation of certain types of tumor cells to nonmalignant phenotypes. In an attempt to discover a more potent compound, a number of bis-functionalized amides, imides, and hydrazine derivatives of HMBA were prepared and evaluated in vitro with the HL-60 human promyelocytic leukemia cell line. Among the compounds evaluated, the 5,5-dimethylhydantoin derivative is almost 10 times more potent than HMBA in inducing differentiation. The bis-imide, diacetyl-HMBA, is both more potent and effective than its parent compound. Six of the 16 compounds evaluated cause at least 20% differentiation. An inverse relationship between the degree of differentiation and the percentage of viable cells is described for HMBA and its analogues.